about
A pathway for tumor necrosis factor-alpha-induced Bcl10 nuclear translocation. Bcl10 is up-regulated by NF-kappaB and phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleusPredictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity.Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer.Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study.A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies.Phosphorylation of Cytidine, Deoxycytidine, and Their Analog Monophosphates by Human UMP/CMP Kinase Is Differentially Regulated by ATP and Magnesium.Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: a meta-analysis of randomized clinical trials.Increasing incidence of brain metastasis in patients with advanced hepatocellular carcinoma in the era of antiangiogenic targeted therapy.Comparison of the phosphorylation of 4'-ethynyl 2',3'-dihydro-3'-deoxythymidine with that of other anti-human immunodeficiency virus thymidine analogs.Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma.Systemic therapy for metastatic urothelial carcinoma.Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway.Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size.Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001.Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma.The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma.OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma.Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: in vitro combined effects and a phase II trial.β-catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma.Association of clinical and dosimetric factors with postoperative pulmonary complications in esophageal cancer patients receiving intensity-modulated radiation therapy and concurrent chemotherapy followed by thoracic esophagectomy.Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection.The chemopreventive compound curcumin is an efficient inhibitor of Epstein-Barr virus BZLF1 transcription in Raji DR-LUC cells.Prognostic value of multidrug resistance 1, glutathione-S-transferase-pi and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy.High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection.The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma.Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma.A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy.Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study.Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy.Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer.Disseminated peritoneal leiomyomatosis responds to systemic chemotherapy.Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma.Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma.Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials.Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and Paclitaxel as first-line treatment.
P50
Q24294485-BDFE54D1-2C84-4EDE-82F5-3E98CDCC8C40Q26784218-4571D641-B83C-4527-8193-BF13E9730B8FQ33370243-67B27F4B-3573-4316-8119-874950A39072Q33370969-404440D6-7150-4912-8784-AB122C44DAB1Q33373555-4CF66B5D-51AA-4CD1-8ABC-44CE5871854DQ33374499-E58A1381-D8A8-4285-865A-522BC8D9DE3FQ33414793-ACCAB51E-928F-417B-AEC6-6795393713E6Q34369253-0AB80FD3-A6D6-41FD-B5A2-4094F986974FQ35540620-EA1684E5-335E-4D39-B970-5B1B9B14AB31Q35584330-B4886F2A-56CB-4927-A192-8BBC600A9F30Q35759090-A24FE039-4019-418F-83E7-E66A68D29A00Q36051537-A48F2723-9722-4141-92B3-62265F85F130Q37028356-3807B8EF-A7AB-4A3F-BBD5-75A88FBF55B8Q37160844-EDF50956-E1A9-4034-B457-BB347BBC7FCBQ37296885-4FE68AB8-AE73-4B43-8BC7-C48A137CA957Q39589474-8F1C1F77-9939-41AD-A2E5-1DB436697FA7Q39612275-B3B34808-3E0A-48EB-B384-E5491B473166Q39673405-30E6F0AF-376B-4B6D-94FC-6F72BBB18FD5Q39893220-37631569-0CB7-49E8-8270-9F8FAAC138C7Q39916403-A25EE376-67C9-49C2-91F3-2B2A570094F4Q40136672-948C82E7-7EB0-4B98-BDF6-F00F0913F4ABQ42206918-353FA79C-1766-464B-990D-50542F1249BFQ42614184-BAA9EA93-8027-4A2E-8AB6-D03508A0D40BQ43008115-EF04E4C5-90AE-46D8-9F53-D40A9AC7776FQ43086833-6CF8C4FF-9312-448C-9F1E-DC366EF62FD9Q43861062-263E565D-127D-48D1-AD8E-63B70254DE7EQ43900332-3A9E6350-1814-4D6C-8F46-5E169EB1AB78Q44077426-5BAAB06D-DCC1-410B-ADB6-266497BA5864Q44141769-57EDB82B-F244-4976-8C81-2E361CBF0E7AQ44392521-EA4ED824-8721-445E-A33F-E02990EC5B1DQ44458159-963297F6-45FE-4E2E-A68F-B8F3A7EF0EB3Q44681461-A4643D01-5825-4ABF-9922-9682114B001EQ45785329-1C9F9FBC-4183-4C33-A6DE-CA3BFAFAC7AAQ45847529-D2681344-8C0D-409E-B9ED-2BD927D54C3DQ46078347-4C3F5569-D423-4DD7-9F82-B065BFE2C420Q46224964-E3884E31-6F06-4D16-8C90-E00DACB5FD0BQ46538715-A55BC6A5-E9F0-4E2E-9F6F-616377A20348Q46543082-9683C3C6-3262-44C9-991D-B76E8A5A3097Q46575959-8140A9CB-8300-479F-8D69-934094D8441CQ46601887-04C505EE-E771-4079-988F-1F14E8E3A4FA
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Chih-Hung Hsu
@ast
Chih-Hung Hsu
@en
Chih-Hung Hsu
@es
Chih-Hung Hsu
@nl
type
label
Chih-Hung Hsu
@ast
Chih-Hung Hsu
@en
Chih-Hung Hsu
@es
Chih-Hung Hsu
@nl
prefLabel
Chih-Hung Hsu
@ast
Chih-Hung Hsu
@en
Chih-Hung Hsu
@es
Chih-Hung Hsu
@nl
P106
P1153
15756011800
P31
P496
0000-0003-0495-973X